Page 20 - Pharma Sector

Flipkart has ended its partnership with us: Medicine e-tailer Sastasundar

Medicine e-tailer Sastasundar on Tuesday said that e-commerce giant Flipkart has ended its partnership in the online pharmacy and healthcare space with it. The Kolkata-based entity also said it has reclaimed its brand's intellectual property rights (IPRs). The Walmart-owned Flipkart had acquired a 75 per cent stake in Sastasundar Marketplace in 2021. An e-mail sent to Flipkart on the development did not elicit any response. "The deal with Flipkart is over and we got back all the intellectual property rights of the Sastasundar brand from it. Now, we will launch our app. In 2021, we had sold a 75 per cent stake in Sastasundar Marketplace Ltd for around Rs 750 crore to Flipkart," Sastasundar Group chairman B L Mittal told PTI. This reclaim transaction did not attract any material investment, he said. Holding company Sastasundar Ventures has re-acquired the brand's IPRs and non-compete rights from Flipkart Health+ through its newly-formed subsidiary, Sastasundar Healthtech Ltd, he ..

Doctors may face suspension in NMC probe over pharma-sponsored trips

This was in violation of the UCPMP rules, which regulate interactions between pharmaceutical companies and HCPs and prohibit foreign trips, gifts, and inducements as unethical marketing practices

Union Budget 2025-26: Customs duty hike likely on key pharma, RE products

Key components in the renewable energy industry such as special bearings, gearboxes, yaw components, wind turbine controllers are currently subjected to a concessional customs duty of 5 per cent

Senores Pharmaceuticals races 17% on robust Q3; profit more than doubles

The rise in Senores Pharmaceuticals share came after the company's strong show in the December quarter (Q3FY25) results

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Venus Remedies share price surges 12% on renewal of EU GMP certification

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by Infarmed, the National Authority of Medicines and Health Products in Portugal

Glenmark Pharma share rises 2% as unit launches blood clotting drug

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

French firm Roquette seeks CCI's clearance for IFF Pharma's biz acquisition

French plant-based ingredient producer Roquette Frres has sought fair trade regulator CCI's approval for the proposed acquisition of the pharma solutions business and certain product lines of International Flavors & Fragrances Inc (IFF). Roquette Frres S.A. is a family-owned French firm active in the production and sale of plant-based ingredients, excipients, and plant proteins for various applications. It has operations in India through several subsidiaries, like Crest Cellulose, Sethness-Roquette India and Roquette India. "The proposed transaction refers to the proposed acquisition by Roquette of the pharma solutions business and certain product lines of the Nourish business (ie, collectively the target business) of IFF by way of Roquette's purchase of equity interest in certain IFF entities that collectively house / are proposed to house the target business," said a notice filed with the CCI on January 16. The target business primarily comprises the operations, and activities ..

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

PAG acquires majority stake in Pravesha Industries for $200 million

PAG had earlier acquired Manjushree Technopack for $1bn

PAG acquires majority stake in pharma company Pravesha Industries

PAG has been investing in India since 2009 and currently manages over $3 billion in assets in the country

Biocon Biologics marks one year as global biosimilars enterprise

It is targeting a $100 m inventory improvement by March

Cipla launches CipAir mobile app for first-line asthma screening in India

The app aims to assess users' likelihood for asthma, thereby enabling timely intervention and management

Booster shot as Medicity set to come up in 200 acres area in Chhattisgarh

Under the project, health facilities with about 5,000 bed capacity would be developed via private investment

Aarti Pharma share price down 5% from day high on order to shut Vapi plant

Aarti Pharma share price: The Gujarat Pollution Control Board has ordered Aarti Pharma to deposit a bank guarantee of Rs 2,50,000

Senores Pharma IPO listing jackpot: Shares debut at bumper 52% premium

Senores Pharma shares listed at Rs 593.70 apiece on the BSE, reflecting a premium of 51.84 per cent over the IPO allotment price of Rs 391

The India story: The journey to becoming the 'pharmacy of the world'

Critical tweaks in laws, spirit of enterprise and the pandemic brought about this transition. Tech and innovation will now define the industry's future

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..

Healthcare sector in India to reach $320 billion by 2028, says report

India's pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year: Great Place To Work report